Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

Stone Ridge’s Predictable Cash Flows: Longevity Income ETFs

by Team Lumida
July 4, 2024
in Health and Longevity
Reading Time: 3 mins read
A A
0
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

  1. Stone Ridge introduces 32 Longevity Income ETFs targeting predictable monthly cash flows for retirees.
  2. Funds invest in US Treasuries and government money markets, with options for inflation protection.
  3. Competitors like BlackRock and T Rowe Price also eye post-retirement income market.

What Happened?

Stone Ridge has filed to launch 32 Longevity Income ETFs, specifically designed to provide regular monthly income for elderly investors. These ETFs target investors who will turn 100 between 2048 and 2063, generating income starting 20 years before that. The funds invest initially in US Treasuries and government money market funds.

A companion suite, the Inflation-Protected Longevity Income ETFs, will invest in Treasury Inflation-Protected Securities. Each ETF aims to generate monthly distributions of $0.0833 per share, totaling $1 per share annually.

Why It Matters?

The introduction of these ETFs addresses a significant gap in the market. Many products focus on asset accumulation rather than converting those assets into predictable cash flows. Stone Ridge’s offering provides a solution for retirees seeking steady income, crucial for financial planning.

The funds’ design, with options for term-income distributions or converting shares into a closed-end fund, offers flexibility. Additionally, the involvement of a market leader in income annuities for actuarial services ensures robust financial planning.

What’s Next?

As competition intensifies among fund firms for post-retirement assets, Stone Ridge’s ETFs could set a new standard. With fees yet to be disclosed, investors should watch for cost details. The funds liquidate in December of the target year, ensuring distributed assets by that time.

Given the market’s response to the Secure Act of 2019, which encouraged guaranteed-income options, expect similar offerings from competitors like BlackRock, Capital Group, and T Rowe Price. Investors should monitor how these ETFs perform compared to traditional retirement income products.

Source: Financial Times
Tags: ETFLongevity Income ETFsRetirement incomeStone Ridge
Previous Post

Bitcoin Crashes Below $59K: $230M in Liquidations Rock Crypto Market

Next Post

Goldman Sachs vs. Fed: $6 Billion Stress Test Showdown

Recommended For You

$399 Signal Ring Claims to Replace the Blood Pressure Cuff — No Calibration, No Subscription, Clinical Trial at Stanford

by Team Lumida
1 day ago
Fingers hold a black smart ring with circuits visible.

Vital Signals, a three-year-old startup, has launched a $399 Signal Ring that claims to track blood pressure as accurately as a traditional arm cuff — without requiring any...

Read more

Novo’s Obesity Pill Commands 89% Market Share — Lilly’s Foundayo Captures Just 11% After Three Months on Market

by Team Lumida
3 days ago
Novo’s Obesity Pill Commands 89% Market Share — Lilly’s Foundayo Captures Just 11% After Three Months on Market

Novo Nordisk's Wegovy pill has seized 89% of new oral obesity pill prescriptions since its January 2026 launch, leaving Eli Lilly's Foundayo — launched in April — with...

Read more

Information Blocking in Healthcare Is Down — But a Stubborn Minority of IT Vendors Keep Doing It Routinely

by Team Lumida
4 days ago
doctor holding red stethoscope

The share of health information exchanges reporting instances of information blocking fell from over 90% in 2019 to 71% in 2025, according to new ONC data — but...

Read more

Novo Nordisk Squeezes Suppliers for Discounts as Eli Lilly Eats Its Lunch in the Obesity Drug Market

by Team Lumida
2 weeks ago
Novo Nordisk Q2 2024 Earnings Highlights

Novo Nordisk has written to suppliers seeking price discounts to protect its cost base as it fights to claw back market share lost to Eli Lilly in the...

Read more

Medicare Launches $50/Month Weight-Loss Drug Coverage Today — With Caveats

by Team Lumida
2 weeks ago
GLP-1 Drugs Are Triggering a Returns Crisis for America’s Apparel Retailers

Medicare's "Bridge" program kicks off July 1, offering Wegovy and Zepbound to 12.5–20 million eligible seniors at a $50 monthly copay — down from up to $450 cash...

Read more

FDA Reverses Rejection of Regenxbio Gene Therapy for Fatal Rare Disease

by Team Lumida
4 weeks ago
FDA Reverses Rejection of Regenxbio Gene Therapy for Fatal Rare Disease

The FDA agreed to reverse its rejection of Regenxbio's Navsunli gene therapy for Hunter syndrome — the third rare-disease drug reversal under new FDA leadership, marking a retreat...

Read more

Nvidia Partners With Abridge to Build an AI Model Trained on Real Doctor-Patient Conversations

by Team Lumida
1 month ago
Nvidia’s AI Demand Surge: Hon Hai Ramps Up Server Production

Nvidia and AI medical note-taking startup Abridge are jointly developing a clinical AI model trained on de-identified doctor-patient conversations, using Nvidia's open Nemotron models as a base —...

Read more

Nearly 90% of Americans Have It and Don’t Know It: First Guidelines Issued for CKM Syndrome

by Team Lumida
1 month ago
people holding us a flag during daytime

The American Heart Association and three major medical societies published the first clinical guidelines for cardiovascular-kidney-metabolic syndrome — a cluster of interconnected conditions tied to excess body fat...

Read more

Employers Are Slashing GLP-1 Coverage as Costs Spiral — And Some Are Adding Weigh-Ins to Keep It

by Team Lumida
1 month ago
GLP-1 Drugs Are Triggering a Returns Crisis for America’s Apparel Retailers

More than a quarter of large companies are adding new criteria for GLP-1 weight-loss coverage while 11% are dropping it altogether, as drug costs balloon and employers struggle...

Read more

GLP-1 Drugs Are Triggering a Returns Crisis for America’s Apparel Retailers

by Team Lumida
1 month ago
GLP-1 Drugs Are Triggering a Returns Crisis for America’s Apparel Retailers

Shoppers on weight-loss drugs are dropping a clothing size every month, flooding retailers with returns — one online suit seller saw a 50% jump — and forcing the...

Read more
Next Post
Goldman’s Big Bet on Wealth Lending: Doubling Down on the Ultra-Rich

Goldman Sachs vs. Fed: $6 Billion Stress Test Showdown

Fed Minutes Reveal Reluctance to Cut Rates Amid Inflation Worries

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

silver and diamond ring on white table

Cadillac’s Iconic Escalade Goes Electric With the Launch of the $127,700 Escalade IQ

April 14, 2025
man wearing gloves and mask holding iron

Fortescue Reports 41% Profit Drop Amid Weaker Iron-Ore Prices and China’s Property Slump

August 26, 2025
Pure Storage Earnings Highlights: Double-Digit Growth and AI Opportunities

Pure Storage Earnings Highlights: Double-Digit Growth and AI Opportunities

August 29, 2024

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018